Introduction
There is no longer any reasonable doubt that adjuvant chemotherapy prolongs survival for premenopausal women with early breast cancer. Indeed, in more than 100 years of research into breast cancer management it is the first form of treatment convincingly shown to have survival benefit. Yet important questions linger over its real clinical value. These include the balance of benefit against morbidity, and the possibility that the treatment effect may be largely endocrine-mediated. For many clinicians whether or not to give adjuvant chemotherapy is still a difficult decision.
New evidence for survival benefit
The rationale for adjuvant chemotherapy is a simple one. Most patients presenting with so-called early breast cancer which appears to be localized to the breast and/or regional nodes in reality already have micro-metastatic disease from which they will eventually die unless they are given effective systemic treatment as an adjunct to surgery.
The first adjuvant chemotherapy trials were started three decades ago,' but real interest in this approach was stimulated by two important trials which were started in the 1970s. The first of these, run by the National Surgical Adjuvant Breast Project (NSABP) Group 50 treated with combination chemotherapy, usually involving CMF. In contrast the survival benefit for post-menopausal women was minimal. Because of the nature of analysis, there are so far no good data on the relationship between survival and duration of follow-up: this may come from further similar analyses in the future. Nevertheless, the statistical methods used are widely accepted as being valid and powerful and the results confirm beyond reasonable doubt that adjuvant chemotherapy does indeed achieve a significant improvement in survival for patients under 50 years old. The dilemma for the clinician lies in deciding whether this survival difference is clinically worthwhile for the patient and whether chemotherapy is the best way to improve survival.
Is this survival improvement clinically worthwhile?
A 30% reduction in mortality is not necessarily as dramatic as it sounds, and depends on the actual mortality in the control group. In the overview analysis the actual percentage difference in survival between treated and non-treated patients was estimated to be around 10% at 5 years follow-up (36% vs 27% dead). In the Milan CMF trial the difference was 14% at 10 years, and in the NSABP trial 24% at 10 years. Whatever figure is chosen, this form of analysis implies that only a small minority of patients will benefit from treatment. This is of course a common problem for many forms of cancer treatment and does not necessarily invalidate the therapeutic approach, but it is an important factor to be taken into account when assessing clinical benefit.
Recently, it has been argued that a simple survival difference at a specific time point may not be the best way to assess overall benefit, and that what should be measured instead is the difference in median survival between treated and untreated patients. How does adjuvant chemotherapy work? Adjuvant chemotherapy was conceived on the reasonable premise that survival might be improved through a direct cytotoxic effect on micro-metastatic tumour cells. However, it is difficult on this basis to explain the recurring observation that such treatment appears to be of significant benefit only in premenopausal women. This raises the important question as to whether its effect is instead mainly endocrine-mediated through ovarian suppression.
It is well established that chemotherapy suppresses ovarian function1 2.13 and most patients receiving CMF chemotherapy develop amenorrhoea.'6 A powerful argument in favour of an endocrine-mediated effect has come from a recent analysis of the Guy's-Christie Hospital CMF trial which showed that prolonged survival occurred only in patients who developed amenorrhoea with treatment.6 Likewise in this analysis, survival benefit was seen only in patients whose tumours were positive for cytoplasmic progestogen receptors (PR), and by implication therefore more likely to be endocrine sensitive. Other trials have so far provided little information on the relationship of survival to PR status, but there are more data on the relationship of amenorrhoea with survival and these tend to contradict the Guy's-Christie study. For example, amenorrhoea did not influence survival in a Danish CMF trial14 or relapse-free survival in the Milan CMF trial in which 37% of patients with amenorrhoea were relapse-free at the time of analysis compared with 32% who did not develop amenorrhoea, compared with 17% in untreated control patients.5 Data from this kind of analysis are therefore circumstantial and at present contradictory.
A second approach to this question comes from the results of trials directly assessing endocrine therapy itself as an adjuvant treatment. First results from adjuvant oophorectomy trials most of which were started many years ago failed to show a convincing survival improvement and this approach fell into disrepute. Recently, however, an overview analysis of these trials with much longer follow-up suggested results very similar to that achieved with adjuvant chemotherapy with a 29% reduction in the odds of death.7 This analysis has to be viewed with caution since the number of patients in oophorectomy trials are very considerably less than for chemotherapy.
In a similar context, two UK multi-centre trials of adjuvant tamoxifen have shown small but significant survival benefits for premenopausal patients with this simple treatment, with follow-up of up to 6 and 8 years. 16 The there is very strong evidence that adjuvant chemotherapy significantly prolongs survival for premenopausal patients with node-positive disease. Whether or not this is of real clinical benefit when balanced against toxicity is not simply a medical question but requires a value judgement from both clinician and patient; in this context, correct supervision of treatment can go a long way towards minimising side effects. Future developments with less toxic drugs or shorter duration treatment may make chemotherapy easier; conversely, simple forms of endocrine therapy may eventually be shown to be almost as effective. As trials continue, open mindedness in assessing new information as it emerges remains the key to coping with these difficult decisions.
